<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Shares of Moderna Inc. MRNA, +3.24% gained 0.5% in premarket trading on Tuesday after the company said it is seeking an update to the conditional authorization of its COVID-19 vaccine in Europe so that it includes children between the ages of 6 and 11 years old. Moderna said earlier this month that it will delay filing for authorization in this age group in the U.S. until the Food and Drug Administration’s review of the myocarditis risk in teens is resolved, likely by January.
...read full article on Market Watch
